Valeant shares have lost more than 90% of their value from a high point of $257 in July 2015. (NYSE:VRX). Credit Suisse Ag invested 0.02% in Valeant Pharmaceuticals International, Inc. The lowest EPS estimate is $0.48 and the highest is $0.86. The firm is expected to report its next earnings report before the market opens on Tuesday, May 8th. (NYSE:VRX)'s short data, trying to figure out market sentiment on which way the market thinks the stock is moving. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.02. However it has a net margin of 27.60%. During the same quarter previous year, the firm earned $1.26 EPS. During the same quarter past year, the company earned $1.26 earnings per share.
Several other research analysts have also weighed in on VRX. ValuEngine lowered Valeant Pharmaceuticals International from a "buy" rating to a "hold" rating in a report on Thursday, March 1st.
Specialty pharma Valeant Pharmaceuticals said Tuesday it will change its name to Bausch Health Companies Inc.as part of a turnaround effort aimed at shaking a reputation marred by accounting scandals and criticism of price hikes on its drugs. HC Wainwright reiterated a "hold" rating and issued a $16.00 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, March 15th. (NYSE:VRX). Winslow Evans & Crocker holds 0.03% of its portfolio in Valeant Pharmaceuticals International, Inc.
Despite the fact that a low P/E ratio may make a stock look like a good buy, factoring in the company's growth rate to get the stock's PEG ratio can tell a different story. Also, CEO Joseph C. Papa purchased 30,000 shares of the business's stock in a transaction on Tuesday, March 13th. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. The company's price to sales ratio for trailing twelve months is 0.73 and price to book ratio for most recent quarter is 1.09, whereas price to cash per share for the most recent quarter is 8.79. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
In other Valeant Pharmaceuticals International news, Director John Paulson bought 7,066,629 shares of the firm's stock in a transaction that occurred on Tuesday, March 6th. The shares were bought at an average price of $15.40 per share, with a total value of $108,826,086.60. The disclosure for this purchase can be found here. The name change, while more cosmetic, is the latest move the company has made to distance itself from the business strategies of its recent past.
Valeant Pharmaceuticals, which owns a Rochester company with a long history in this area, will be adopting some of that heritage. Great West Life Assurance Co. Two Sigma Advisers LP boosted its position in Valeant Pharmaceuticals International by 7,294.2% during the 4th quarter. Keybank National Association OH acquired a new position in Valeant Pharmaceuticals International during the 4th quarter valued at approximately $208,000. (NYSE:TWX) showed a change of -0.62% over the last week and performed -2.36% over the last month while its year to date (YTD) performance revealed an activity trend of 1.19%. EPS is an indicator of company profit because the more earnings a company can generate per share, the more valuable each share is to investors. (NYSE:VRX) for 12,275 shares. Gramercy Funds Management Llc who had been investing in Valeant Pharmaceuticals Intl (Call) for a number of months, seems to be bullish on the $6.29 billion market cap company.
Investors also seem to have been excited by news that the pharmaceutical giant had raised its revenue guidance for 2018 during the release of the earnings report.
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company.
Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices.